Sterile growth, with tariff drag
- STERIS is a picks-and-shovels healthcare company, selling sterilizers, consumables, services, and contract sterilization.
- Fiscal 2026 revenue rose 8.7% to $5.94 billion, with growth across Healthcare, AST, and Life Sciences.
- Life Sciences capital equipment grew 15.5%, a clear rebound after a weak spending cycle.
- The Illinois ethylene oxide legal overhang is smaller after a $48.2 million settlement for substantially all Cook County personal injury claims.
- The main pushback is margin pressure from tariffs and inflation, plus normal swings in capital equipment orders.
Steady demand, harder costs
STERIS looks stronger than it did during the Life Sciences downturn. In fiscal 2026, all three segments grew on a constant currency organic basis: Healthcare grew 7.6%, AST grew 6.7%, and Life Sciences grew 6.7%. Life Sciences also showed a real capital equipment rebound, with capital revenue up 15.5%.
The bull case is simple. Hospitals, medical device makers, and drug companies need clean rooms, sterile tools, and sterilized products. STERIS sells the equipment, then keeps earning from consumables and services tied to that installed base. Fiscal 2026 free cash flow was $982.9 million, and the board authorized a new $1.0 billion share repurchase program in May 2026.
The bear case is not about demand falling apart. It is about how much profit STERIS keeps from that demand. Gross margin improved only slightly to 44.2% in fiscal 2026 from 44.0% in fiscal 2025 because tariffs and inflation offset much of the benefit from pricing, productivity, and operating fixes.
Finn's view is balanced. The business is high quality and financially healthy, but the stock still needs proof that margins can expand while tariffs, inflation, and capital equipment cycles remain active risks.
Installed base, repeat spend
STERIS makes money in three ways: selling capital equipment, selling consumables used with that equipment, and providing services. Capital equipment includes sterilizers, surgical tables, automated endoscope reprocessors, and systems used in drug manufacturing. Consumables include cleaning chemistries, sterility assurance products, endoscopy accessories, and other items customers keep buying.
The model works because the first equipment sale can lead to years of follow-on revenue. A hospital that buys sterilization equipment also needs service, maintenance, parts, and supplies. A medical device company that uses STERIS for contract sterilization often needs that service every time it ships product.
This repeat-spend base makes STERIS more stable than a pure equipment seller. Still, the company is not immune to cycles. When hospitals, pharma companies, or device makers delay large projects, capital equipment orders can slow. That already showed up in AST capital equipment in fiscal 2026, even as Life Sciences recovered.
What STERIS sells
Healthcare equipment
STERIS sells sterilizers, surgical tables, lights, operating room systems, and endoscope reprocessors to hospitals and care sites. These are large purchases, so timing can move quarter to quarter.
Healthcare consumables
Consumables include sterilization chemistries, sterility assurance products, endoscopy accessories, instruments, and cleaning products. Demand is tied to procedure volumes and daily hospital work.
Healthcare services
STERIS provides maintenance, installation, instrument repair, scope repair, and outsourced reprocessing. These services help turn the installed equipment base into repeat revenue.
Applied Sterilization Technologies
AST provides contract sterilization and lab testing for medical device and biopharma customers. It is a high-margin segment, with fiscal 2026 operating margin of 46.1%.
Life Sciences equipment
This line sells equipment for aseptic drug manufacturing and critical environments. It rebounded in fiscal 2026, with Life Sciences capital revenue up 15.5%.
Life Sciences consumables and services
These products and services support pharma and research customers after equipment is installed. In fiscal 2026, Life Sciences consumables grew 7.6% and services grew 4.9%.
Healthcare carries the mix
Segment shares use fiscal 2026 revenue from the Form 10-K. Healthcare is the largest piece, so hospital procedure volumes and hospital capital budgets matter most.
What could go wrong
Tariffs and inflation eat the price gains
High impact · Medium oddsSTERIS raised prices and improved productivity in fiscal 2026, but tariffs and inflation still held back gross margin. Total gross margin rose only to 44.2% from 44.0%. If tariff pressure rises or cost inflation stays sticky, earnings growth could lag revenue growth.
Ethylene oxide claims move beyond Illinois
High impact · Medium oddsSTERIS agreed to pay up to $48.2 million to resolve substantially all personal injury claims related to ethylene oxide exposure pending in Cook County, Illinois. That removed a major known overhang. The open question is whether other jurisdictions or regulators create new costs.
Capital equipment turns down again
Medium impact · Medium oddsLife Sciences capital equipment recovered in fiscal 2026, but capital orders are still cyclical. AST capital equipment declined during the same year, which shows the risk is not gone. Large hospital, pharma, or device maker projects can be delayed when budgets tighten.
Trade rules add supply chain friction
Medium impact · Medium oddsThe internal watch item is the evolving trade environment, including possible USMCA changes. New trade rules could raise costs or slow cross-border supply chains. That would make margin expansion harder even if demand stays healthy.
Buybacks fail to create value
Medium impact · Low oddsSTERIS authorized a new $1.0 billion share repurchase program in May 2026. Buybacks can help owners when done at fair prices and funded by strong cash flow. They can disappoint if the company buys too aggressively while margins are under pressure or the stock is expensive.
In one breath
What does STERIS do?
STERIS helps hospitals, medical device companies, and drug makers keep products and care settings sterile. It sells sterilization equipment, consumables, maintenance services, contract sterilization, and life sciences products.
Why is STERIS considered recurring revenue?
Many customers keep buying consumables and services after they buy STERIS equipment. The company also earns service revenue from contract sterilization and equipment maintenance, which tends to repeat with customer activity.
What changed most recently for STERIS?
Life Sciences capital spending rebounded in fiscal 2026, with capital revenue up 15.5%. STERIS also quantified and largely resolved a major Illinois ethylene oxide legal overhang through a $48.2 million settlement.
What is the biggest risk for STERIS stock?
The biggest near-term risk is margin pressure. Tariffs and inflation are offsetting some of the benefit from price increases, productivity, and higher volumes.